S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:BDTX

Black Diamond Therapeutics (BDTX) Stock Price, News & Analysis

$4.90
-0.19 (-3.73%)
(As of 03/27/2024 ET)
Today's Range
$4.74
$5.17
50-Day Range
$2.67
$5.74
52-Week Range
$1.43
$6.85
Volume
403,015 shs
Average Volume
606,834 shs
Market Capitalization
$253.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.75

Black Diamond Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
119.4% Upside
$10.75 Price Target
Short Interest
Healthy
3.50% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.21mentions of Black Diamond Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.76) to ($1.85) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.45 out of 5 stars

Medical Sector

511th out of 939 stocks

Biological Products, Except Diagnostic Industry

81st out of 153 stocks

BDTX stock logo

About Black Diamond Therapeutics Stock (NASDAQ:BDTX)

Black Diamond Therapeutics, Inc., a clinical-stage precision oncology medicine company, focuses on the discovery and development of therapies for patients with genetically defined cancers. The company's lead product candidate, BDTX-1535, a brain-penetrant, mutant selective, irreversible EGFR MasterKey inhibitor, designed to inhibit a family of oncogenic mutations, currently under Phase 1 clinical trial. It also develops BDTX-4933, a brain penetrant RAF MasterKey inhibitor, designed to be a brain penetrant and highly selective and potent inhibitor of oncogenic BRAF Class I, II, III and active RAF dimers, expected to initiate Phase 1 clinical trial. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

BDTX Stock Price History

BDTX Stock News Headlines

The Small Biotech with a BIG Cancer Solution
There's a new cancer treatment so precise, it's been called a "smart bomb." One that can deliver a toxic payload directly to tumors while bypassing healthy cells.
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
BDTX Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics Inc (BDTX)
Black Diamond Therapeutics Inc.
Solitario: Q3 Earnings Snapshot
Black Diamond Therapeutics Inc Ordinary Shares BDTX
Black Diamond Therapeutics (BDTX) Receives a Buy from Piper Sandler
See More Headlines
Receive BDTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Black Diamond Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/11/2023
Today
3/27/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:BDTX
Web
N/A
Fax
N/A
Employees
54
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.75
High Stock Price Target
$12.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+119.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-82,440,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.26 per share

Miscellaneous

Free Float
47,027,000
Market Cap
$253.43 million
Optionable
Optionable
Beta
2.65
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Mark A. Velleca M.D. (Age 60)
    Ph.D., CEO, President & Chairman
    Comp: $43.89k
  • Dr. David M. Epstein Ph.D. (Age 65)
    Co-Founder & Director
    Comp: $885.08k
  • Dr. Fang Ni Pharm.D. (Age 37)
    CFO, Principal Financial Officer and Chief Business Officer
    Comp: $656.33k
  • Mr. Brent Hatzis-Schoch Esq.Mr. Brent Hatzis-Schoch Esq. (Age 59)
    J.D., COO & General Counsel
    Comp: $683.29k
  • Dr. Elizabeth Buck Ph.D. (Age 49)
    Co-Founder & Chief Scientific Officer
    Comp: $340.47k
  • Ms. Erika Jones (Age 39)
    VP of Finance, Corporate Controller & Principal Accounting Officer
  • Ms. Elizabeth L. Montgomery (Age 52)
    Chief People Officer
  • Dr. Sergey Yurasov M.D. (Age 55)
    Ph.D., Chief Medical Officer
  • Ms. Melanie Morrison
    Chief Development Officer

BDTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Black Diamond Therapeutics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Black Diamond Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BDTX shares.
View BDTX analyst ratings
or view top-rated stocks.

What is Black Diamond Therapeutics' stock price target for 2024?

4 Wall Street analysts have issued 12 month target prices for Black Diamond Therapeutics' stock. Their BDTX share price targets range from $10.00 to $12.00. On average, they predict the company's stock price to reach $10.75 in the next twelve months. This suggests a possible upside of 119.4% from the stock's current price.
View analysts price targets for BDTX
or view top-rated stocks among Wall Street analysts.

How have BDTX shares performed in 2024?

Black Diamond Therapeutics' stock was trading at $2.81 at the beginning of 2024. Since then, BDTX shares have increased by 74.4% and is now trading at $4.90.
View the best growth stocks for 2024 here
.

When is Black Diamond Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our BDTX earnings forecast
.

How were Black Diamond Therapeutics' earnings last quarter?

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) announced its earnings results on Friday, August, 11th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.02.

What other stocks do shareholders of Black Diamond Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Black Diamond Therapeutics investors own include Alector (ALEC), Alteryx (AYX), Editas Medicine (EDIT), Gossamer Bio (GOSS), Micron Technology (MU), NVIDIA (NVDA), Homology Medicines (FIXX), II-VI (IIVI), Intel (INTC) and Invitae (NVTA).

When did Black Diamond Therapeutics IPO?

Black Diamond Therapeutics (BDTX) raised $151 million in an IPO on Thursday, January 30th 2020. The company issued 8,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies and Cowen served as the underwriters for the IPO and Canaccord Genuity was co-manager.

Who are Black Diamond Therapeutics' major shareholders?

Black Diamond Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Bellevue Group AG (16.53%), Vanguard Group Inc. (3.77%), Vanguard Group Inc. (3.77%), Verition Fund Management LLC (3.01%), Blue Owl Capital Holdings LP (1.35%) and Newtyn Management LLC (0.54%). Insiders that own company stock include Ali Behbahani, Brent Hatzis-Schoch, Christopher D Roberts, David M Epstein, Fang Ni and Growth N V Biotech.
View institutional ownership trends
.

How do I buy shares of Black Diamond Therapeutics?

Shares of BDTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BDTX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners